Melody Cobleigh

机构：Rush University Medical Center, Rush University · ORCID：0000-0001-6385-4693

发表论文 210 篇 · 总被引 21500 次 · h-index 46

代表论文

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer (2022 · Annals of Oncology · 被引 476)
• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (2023 · Journal of Clinical Oncology · 被引 149)
• Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment (2024 · Journal for ImmunoTherapy of Cancer · 被引 71)
• Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) (2024 · Journal of Clinical Oncology · 被引 36)
• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer (2023 · Journal of Clinical Oncology · 被引 36)
• Comparison of gut microbiome composition in colonic biopsies, endoscopically-collected and at-home-collected stool samples (2023 · Frontiers in Microbiology · 被引 28)